- Home
- GIPR vs RDHL Comparison
GIPR vs RDHL Comparison
Compare GIPR & RDHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GIPR | RDHL |
|---|---|---|
| Founded | 2015 | 2009 |
| Country | United States | Israel |
| Employees | 4 | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1M | 5.6M |
| IPO Year | N/A | 2012 |
Fundamental Metrics
Financial Performance| Metric | GIPR | RDHL |
|---|---|---|
| Price | $0.36 | $0.92 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 98.3K | 30.7K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $1.12 | $381.91 |
| Revenue Next Year | $0.52 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.37 | $0.88 |
| 52 Week High | $1.99 | $3.46 |
Technical Indicators
Market Signals| Indicator | GIPR | RDHL |
|---|---|---|
| Relative Strength Index (RSI) | 28.41 | 35.58 |
| Support Level | N/A | $0.91 |
| Resistance Level | $0.87 | $1.07 |
| Average True Range (ATR) | 0.06 | 0.06 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 0.00 | 17.90 |
Price Performance
Historical ComparisonAbout GIPR Generation Income Properties Inc.
Generation Income Properties Inc is an internally managed real estate investment company focused on acquiring and managing income-producing retail, office and industrial properties net leased to high-quality tenants in markets throughout the United States. Its key source of revenue is the rental income. The company holds properties in Alabama, Arizona, Colorado, the District of Columbia, Florida, Illinois, North Carolina and Virginia.
About RDHL Redhill Biopharma Ltd.
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is dedicated to advancing its development pipeline of clinical-stage therapeutic candidates. It also commercializes GI-related products in the U.S., including Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). Currently, the company's pipeline consists of five therapeutic candidates: Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, the majority of which are in clinical development.